Sanofi SA (NYSE:SNY) – Jefferies Financial Group issued their Q1 2019 EPS estimates for Sanofi in a report released on Thursday, March 14th. Jefferies Financial Group analyst P. Welford forecasts that the company will post earnings of $0.72 per share for the quarter. Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Sanofi’s Q2 2019 earnings at $0.66 EPS, Q3 2019 earnings at $1.14 EPS, Q4 2019 earnings at $0.72 EPS, FY2019 earnings at $3.26 EPS, FY2020 earnings at $3.58 EPS, FY2021 earnings at $3.90 EPS, FY2022 earnings at $4.16 EPS and FY2023 earnings at $4.12 EPS.
Several other research analysts have also recently issued reports on the company. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating and set a $46.00 price objective for the company. in a research report on Saturday, January 26th. Morgan Stanley began coverage on Sanofi in a research report on Friday, December 14th. They issued an “equal weight” rating for the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Tuesday, December 4th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, November 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, February 28th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $51.00.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Thursday, February 7th. The company reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.01. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $9 billion during the quarter, compared to the consensus estimate of $9 billion. During the same period last year, the company earned $1.06 earnings per share. The company’s revenue for the quarter was up 3.5% on a year-over-year basis.
Hedge funds have recently made changes to their positions in the company. Essex Savings Bank purchased a new position in shares of Sanofi in the fourth quarter valued at $30,000. Claybrook Capital LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $31,000. Executive Wealth Management LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $34,000. Berman Capital Advisors LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $44,000. Finally, Global Retirement Partners LLC increased its position in shares of Sanofi by 420.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,040 shares of the company’s stock valued at $45,000 after buying an additional 840 shares in the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.
In other news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.00% of the company’s stock.
The company also recently declared an annual dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 8th will be given a $1.7395 dividend. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s dividend payout ratio is currently 38.34%.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Fiduciary
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.